Altimmune Inc (NASDAQ: ALT) On Tuesday, plunged -4.78% from the previous trading day, before settling in for the closing price of $6.70. Within the past 52 weeks, ALT’s price has moved between $2.09 and $14.84.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 115.21% over the past five years. The company achieved an average annual earnings per share of 16.61%. With a float of $70.48 million, this company’s outstanding shares have now reached $70.68 million.
Let’s look at the performance matrix of the company that is accounted for 59 employees. In terms of profitability, gross margin is -4899.02%, operating margin of -23785.57%, and the pretax margin is -24778.97%.
Altimmune Inc (ALT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Altimmune Inc is 0.83%, while institutional ownership is 60.20%. The most recent insider transaction that took place on Aug 19 ’24, was worth 110,547. In this transaction Director of this company sold 16,011 shares at a rate of $6.90, taking the stock ownership to the 41,958 shares.
Altimmune Inc (ALT) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.39 earnings per share (EPS) for the period topping the consensus outlook (set at -0.42) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.61% per share during the next fiscal year.
Altimmune Inc (NASDAQ: ALT) Trading Performance Indicators
Altimmune Inc (ALT) is currently performing well based on its current performance indicators. A quick ratio of 11.30 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1105.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.52 in one year’s time.
Technical Analysis of Altimmune Inc (ALT)
Altimmune Inc (NASDAQ: ALT) saw its 5-day average volume 1.58 million, a negative change from its year-to-date volume of 4.22 million. As of the previous 9 days, the stock’s Stochastic %D was 22.78%. Additionally, its Average True Range was 0.47.
During the past 100 days, Altimmune Inc’s (ALT) raw stochastic average was set at 26.15%, which indicates a significant increase from 17.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.13% in the past 14 days, which was lower than the 85.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.68, while its 200-day Moving Average is $7.84. Nevertheless, the first resistance level for the watch stands at $6.67 in the near term. At $6.96, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.16. If the price goes on to break the first support level at $6.18, it is likely to go to the next support level at $5.98. Assuming the price breaks the second support level, the third support level stands at $5.69.
Altimmune Inc (NASDAQ: ALT) Key Stats
Market capitalization of the company is 453.43 million based on 70,902K outstanding shares. Right now, sales total 430 K and income totals -88,450 K. The company made 10 K in profit during its latest quarter, and -24,640 K in sales during its previous quarter.
